In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.Topics include:<ul><li>Currently approved ICIs</li><li>Role of biomarker and PD-L1 testing in advanced NSCLC</li><li>Strategies to individualize ICI treatment for patients with advanced NSCLC</li><li>Strategies for identifying and managing immune-related adverse events in patients treated with ICI</li></ul>Presenter: Sandip P. Patel, MD Associate Professor Department of Medicine Division of Hematology/Oncology University of California – San Diego La Jolla, California Link to full program: <a href="https://bit.ly/39vuCHC" target="_blank">https://bit.ly/39vuCHC</a>

ASCO 2022: Advances in CLL/SLL

Practicing Clinicians Exchange keeps advanced practice providers up to date with timely interviews from the front lines on current advances and best practices in medicine. Many of the podcasts are available for CE/CME credit.